FDA Accepts NDA for 177Lu-edotreotide in GEP-NETs | Targeted Oncology

Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field … news release. ¹ “In the [p]hase 3 COMPETE trial, ¹⁷⁷Lu …